• Japanese
  • Korean
  • Chinese
Cover Image

Product Profiles: Insulin Antidiabetics - Key developers compete for basal insulins market

Abstract

Introduction

The basal insulins are the most successful insulin class, with other insulin classes demonstrating high substitution or low and declining sales. Current basal insulins offer good safety and emerging therapies are not expected to improve efficacy significantly. However, the launch of two late-stage pipeline products Degludec and DegludecPlus in 2012 - 13 will alter market dynamics.

Features and benefits

  • Understand Datamonitor's independent appraisal of marketed insulin brands and key pipeline agents indicated for treating type 1 and type 2 diabetes.
  • Illustrate how pipeline and marketed insulins compare to one another in terms of clinical and commercial attributes.
  • Review important clinical developments for key pipeline agents with analysis of the latest clinical trial data.
  • Understand how marketed insulin brands are positioned in the diabetes treatment algorithm and how they are perceived by prescribers.
  • Determine to what extent future insulin therapies satisfy the main clinical unmet needs in the treatment of type 1 and type 2 diabetes.

Highlights

With strong marketing and sales resources committed by Novo Nordisk, late-stage basal insulin Degludec (insulin degludec) will offer strong competition to class leader Lantus (insulin glargine; Sanofi) and largely cannibalize predecessor Levemir (insulin detemir; Novo Nordisk).

Key patents for blockbuster Lantus will expire from 2014 - 15. However, the threat of biosimilar insulin is expected to have less impact than typical small molecule generics, as physicians are expected to be reluctant to introduce potential additional variability into patients' insulin treatment regimens.

Novo Nordisk, Sanofi, and Eli Lilly are also the only companies with promising insulin products in late stage development. Alternative insulin delivery mechanisms under development, such as MannKind's Afrezza (inhaled insulin), are not expected to make it to market in the near term.

Your key questions answered

  • What is the gold-standard basal insulin for diabetes?
  • How are marketed brands positioned in the insulin antidiabetics treatment algorithm?
  • Which are the most likely insulin antidiabetics to emerge from the pipeline and how will they impact the way diabetes is managed?
  • What are the comparative strengths and weaknesses of the key insulin antidiabetics and pipeline insulin candidates?

Table of Contents

OVERVIEW

  • Catalyst
  • Summary

EXECUTIVE SUMMARY

  • Strategic scoping and focus
  • Datamonitor key findings
  • Related reports
  • Published diabetes reports

PRODUCT OVERVIEW

  • Insulin use in type 1 and type 2 diabetes
  • Insulin coverage in this report

MARKETED PRODUCT PROFILES

  • Basal insulin class overview
  • Lantus (insulin glargine; Sanofi)
    • Drug profile
    • Development overview
    • SWOT analysis
    • Product positioning
    • Physician perception of Lantus
    • Clinical and commercial attractiveness
  • Levemir (insulin detemir; Novo Nordisk)
    • Drug profile
    • Development overview
    • SWOT analysis
    • Product positioning
    • Physician perception of Levemir
    • Clinical and commercial attractiveness
  • Other marketed insulin antidiabetics
    • Fast-acting insulins
    • Premixed insulins

PIPELINE PRODUCT PROFILES

  • Degludec (insulin degludec; Novo Nordisk)
    • Drug profile
    • Development overview
    • SWOT analysis
    • Satisfaction of unmet needs
    • Clinical and commercial attractiveness
  • DegludecPlus (insulin degludec + insulin aspart; Novo Nordisk)
    • Drug profile
    • Development overview
    • SWOT analysis
    • Satisfaction of unmet needs
    • Clinical and commercial attractiveness
  • Other insulin antidiabetics in development
    • LY2605541 (Eli Lilly/Boehringer Ingelheim)
    • Improved basal insulin formulations
    • Non-injected insulin formulations

BIBLIOGRAPHY

  • Journal papers and presentations
  • Press releases
  • Websites
  • Datamonitor reports

APPENDIX

  • Exchange rates
  • Datamonitor drug assessment scorecard
  • Contributing experts
  • Report methodology

TABLES

  • Table: Key marketed and pipeline insulin products for type 1 and type 2 diabetes, 2012
  • Table: Key marketed basal insulins by onset and duration of action, 2012
  • Table: Lantus (insulin glargine; Sanofi) - drug profile, 2012
  • Table: Overview of pivotal trial data for Lantus (insulin glargine; Sanofi) in diabetes, 2012
  • Table: Datamonitor drug assessment summary of Lantus (insulin glargine; Sanofi) for diabetes, 2012
  • Table: Levemir (insulin detemir; Novo Nordisk) - drug profile, 2012
  • Table: Overview of pivotal trial data for Levemir (insulin detemir; Novo Nordisk) in diabetes, 2012
  • Table: Datamonitor drug ass essment summary of Levemir (insulin detemir; Novo Nordisk) for diabetes, 2012
  • Table: Degludec (insulin degludec; Novo Nordisk) - drug profile, 2012
  • Table: Overview of pivotal published trial data for Degludec (insulin degludec; Novo Nordisk) in diabetes, 2012
  • Table: Degludec (insulin degludec; Novo Nordisk) - completed and ongoing Phase III trials, 2010 - 12
  • Table: Ability of Degludec (insulin degludec; Novo Nordisk) vs basal insulin class comparator Lantus (insulin glargine; Sanofi) to address unmet needs in diabetes, 2012
  • Table: Datamonitor drug assessment summary of Degludec (insulin degludec; Novo Nordisk) for diabetes, 2012
  • Table: DegludecPlus (insulin degludec + insulin aspart; Novo Nordisk) - drug profile, 2012
  • Table: Overview of pivotal published trial data for DegludecPlus (insulin degludec + insulin aspart; Novo Nordisk) in diabetes, 2012
  • Table: DegludecPlus (insulin degludec + insulin aspart; Novo Nordisk) - completed and ongoing Phase III trials, 2010 - 12
  • Table: Ability of DegludecPlus (insulin degludec + insulin aspart; Novo Nordisk) vs basal insulin class comparator Lantus (insulin glargine; Sanofi) to address unmet needs in diabetes
  • Table: Datamonitor drug assessment summary of DegludecPlus (insulin degludec + insulin aspart; Novo Nordisk) for diabetes, 2012
  • Table: Exchange rates to US dollars, annual average for 2011
  • Table: Datamonitor's drug assessment parameters for key late-stage insulin antidiabetics, 2012

FIGURES

  • Figure: Datamonitor's drug assessment summary for insulin antidiabetics, 2012
  • Figure: Lantus brand franchise (insulin glargine; Sanofi): SWOT analysis, 2012
  • Figure: Criteria for choosing a basal insulin in the seven major markets, 2011
  • Figure: Datamonitor drug assessment summary of Lantus (insulin glargine; Sanofi) for diabetes, 2012
  • Figure: Levemir brand franchise (insulin detemir; Novo Nordisk) SWOT analysis in diabetes, 2012
  • Figure: Datamonitor drug assessment summary of Levemir (insulin detemir; Novo Nordisk) for diabetes, 2012
  • Figure: Degludec (insulin degludec, Novo Nordisk) - SWOT analysis, 2012
  • Figure: Datamonitor's drug assessment summary for Degludec (insulin degludec; Novo Nordisk), 2012
  • Figure: DegludecPlus (insulin degludec + insulin aspart; Novo Nordisk) - SWOT analysis, 2012
  • Figure: Datamonitor's competitive positioning analysis of DegludecPlus (insulin degludec + insulin aspart; Novo Nordisk), 2010
Show More
Pricing